SITC 2024 Poster 1004

3D Ex Vivo Patient Tissue Platform Feasibility for Testing Drug Responses in Primary and Metastatic Colorectal Cancer

Ezgi Kaya Aksoy, Niels Meesters, Sander Basten, Talita Stessuk, Jolie Flach, Luca Gandini, Saskia de Man, Lois Van der Drift, Emma Spanjaard, Leo Price, and Nataliia Beztsinna

Discover Crown Bioscience’s 3D Ex Vivo Patient Tissue (EVPT) platform, a cutting-edge approach for evaluating drug responses in colorectal cancer, including both primary and metastatic samples. This innovative platform maintains the tumor microenvironment, allowing for more accurate assessments of immunotherapy and chemotherapy responses. Gain insights into how the EVPT platform can accelerate preclinical testing and support more predictive drug development strategies for colorectal cancer treatment.

Download this Poster to Discover:

• Platform Overview and Capabilities: Learn about the 3D EVPT platform, which uses short-term 3D tumor cultures to retain the native tumor microenvironment, enabling precise drug response evaluations.
  
  
• Methodology: Understand the process of embedding minimally processed tumors in hydrogel and subjecting them to various therapies, including chemotherapy, targeted therapies, and immunotherapies.
  
  
• Testing Across Cancer Types: Discover how the platform was used to assess both primary and metastatic CRC samples, providing valuable comparisons in drug response.
  
  
• Drug Response and Sensitivity Analysis: Review detailed findings on drug sensitivity for CRC samples, including chemotherapy resistance patterns in metastatic cases.
  
  
• High-Content Imaging (HCI) and Immunohistochemistry (IHC): Explore how HCI and IHC analyses were employed to examine immune cell infiltration and other markers within the tumor microenvironment.
  
  
• Results and Predictive Value: See the key results on drug response heterogeneity across primary and metastatic samples, supporting the feasibility of using the EVPT platform for accurate preclinical evaluation.
  
  
• Clinical Relevance: Learn how these findings can inform more tailored therapeutic approaches, guiding drug development efforts for both early-stage and metastatic colorectal cancer.

Download the Poster Now!